Related Experiment Video
Updated: Aug 15, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
[Aspergillus bronchitis and aspergilloma treated successfully with voriconazole]
N Freymond1, J-B Le Loch, G Devouassoux
1Service de Pneumologie et d'Immunologie Clinique, Centre Hospitalier Lyon Sud, Pierre Bénite, France. nathalie.freymond@chu-lyon.fr
Introduction:
Aspergillus fumigatus is a ubiquitous soil-dwelling organism, which can cause both aspergillomas which develop in a preformed lung cavity, and aspergillus bronchitis. The two pathologies can occasionally co-exist, notably in patients with of cystic fibrosis.
Case Report:
We describe a 57 year old patient, with diffuse bronchiectasis, who developed aspergillus bronchitis as well as an aspergilloma complicating a cavity caused by an atypical mycobacterial infection. After one month of therapy with voriconazole the aspergilloma had decreased in size and the endobronchial changes had resolved.
Conclusion:
This case report illustrates that in addition to its established role for the treatment of invasive aspergillosis, voriconazole is a promising new therapy for the treatment of aspergilloma and aspergillus bronchitis.
Insights
This case report highlights voriconazole as an effective treatment for pulmonary aspergilloma and aspergillus bronchitis, common fungal lung infections. The study shows significant improvement in a patient with these conditions.
Area of Science:
- Mycology
- Pulmonology
- Infectious Diseases
Background:
- Aspergillus fumigatus is a common soil fungus causing lung infections like aspergilloma and aspergillus bronchitis.
- These conditions can occur together, particularly in cystic fibrosis patients.
Observation:
- A 57-year-old patient with diffuse bronchiectasis presented with both aspergilloma and aspergillus bronchitis.
- The aspergilloma complicated a lung cavity caused by atypical mycobacterial infection.
Findings:
- Treatment with voriconazole for one month led to a reduction in aspergilloma size.
- Endobronchial changes associated with aspergillus bronchitis resolved after voriconazole therapy.
Implications:
- Voriconazole demonstrates potential as a novel therapeutic option for aspergilloma and aspergillus bronchitis.
- This expands its utility beyond invasive aspergillosis treatment.
Related Concept Videos
Antifungal Agents
Candidiasis
Cryptococcal Meningitis
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
COPD: Management Using Bronchodilators and Corticosteroids
Fungal Phylum Ascomycota